Loading, Please Wait...
IRVINE, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it will present at the Fourth Annual Robins Equity Research Roundup, September 24, 25, and 26 in Portland, Oregon. The Hancock Jaffe presentation will be on Tuesday, September 25th at 10:30 a.m. Pacific time.
The Robins Equity Research Roundup features a select group of up and coming public and private companies and attracts professional money managers and high net worth investors. The conference is hosted by Marc Robins, a well-known fund manager, publisher, and former equity analyst who has a large following among the micro-cap investors. Each year, Marc Robins personally selects a small group of companies that he introduces to the investing community.
“We have such a compelling story and are going to start to present at investor conferences to create awareness for Hancock Jaffe,” said Robert Berman, Hancock Jaffe’s CEO, who will be presenting at the conference. “With several meaningful milestones for our VenoValve and CoreoGraft that we expect to achieve in the coming weeks, it is just a matter of time before we begin to gain traction among the investing community.”
Hancock Jaffe’s VenoValve® is a potential treatment and cure for Chronic Venous Insufficiency, a debilitating condition that afflicts approximately 4.5 million people in the U.S., and results in up to $46 billion in annual medical costs. HJLI expects to begin human testing of the VenoValve in December of 2018. Hancock Jaffe’s CoreoGraft® is a tissue based, off-the-shelf conduit to be used as a graft during coronary artery bypass surgery. The CoreoGraft could potentially eliminate the need for doctors to harvest veins from the patients’ arm or leg, an invasive and painful procedure that is subject to complications.
About Hancock Jaffe Laboratories, Inc.
HJLI specializes in developing and manufacturing bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has three product candidates: the porcine tissue based VenoValve®, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venue Insufficiency; the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery, and a porcine tissue based heart valve, which based upon its relatively small size and increased output, is an ideal candidate for pediatric aortic/mitral valve replacement.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the performance of the new board members described herein) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
HJLI Press Contacts: